Rheumatoid Arthritis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Rheumatoid Arthritis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis


Rheumatoid Arthritis Drugs Market is expected to increase to US$ 49.86 Billion by 2030, according to Renub Research. Rheumatoid Arthritis (RA) is an autoimmune condition characterized by inflammation and joint pain. It occurs when the immune system malfunctions and targets the synovium, the lining of the joints. Generally, RA affects symmetrical joints on both sides of the body, like both hands and knees. The lungs, heart, eyes, and/or circulatory system are just a few examples of additional body systems that RA may occasionally affect. Approximately 40% of people with rheumatoid arthritis have symptoms in several bodily areas, including nerve tissue, eyes, lungs, salivary glands, and skin. The degree of signs and symptoms may vary, and in some situations, they may be completely absent. Females are more affected than males, with 2.5 females for every male. Rheumatoid Arthritis can appear as early as the age of 16 and last until the age of 40.

In a healthy individual, the immune system battles foreign invaders like bacteria and viruses. An autoimmune illness like RA occurs when the immune system mistakes the body's cells as foreign invaders and unleashes inflammatory chemicals that strike those cells. In RA, it targets the synovium, the tissue lining a joint that secretes a fluid to facilitate smooth movement of the joint. Moving the joint may be challenging due to the thickening of the inflammatory synovium, which makes the affected area of the joint feel uncomfortable, tender, and swollen.

In May 2023, Eli Lilly and Company's phase 2a research on peresolimab in rheumatoid arthritis (RA) revealed positive findings. Peresolimab indicated effectiveness and equal adverse event rates to the placebo group, therefore satisfying the primary aim of the research. These findings give preliminary clinical evidence of the utility of activating the endogenous PD-1 inhibitory pathway in the treatment of rheumatologic disorders. The study looked at the safety and efficacy of peresolimab in adults with moderate-to-severe RA who had not responded well to prior conventional, biologic, or synthetic disease-modifying antirheumatic medications (DMARDs).

Rheumatoid Arthritis Drugs market is projected to grow at a CAGR of 4.72% from 2022 to 2030

The global prevalence of rheumatoid arthritis (RA) was calculated to be 0.46 percent in the paper ""The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a “stematic review"" that was published in Rheumatology International. The market will grow as a result of increased adoption of therapies for the treatment of RA. The main forces behind the expansion of the global rheumatoid arthritis drugs market are the availability of pricey medications and efficient payment methods. The global rheumatoid arthritis drugs market is likely to benefit from the increasing prevalence of the condition, the emergence of biosimilars and biologics, and unambiguous tyrannical regulations. It is anticipated that increasing medical service costs, particularly in developed areas, and developing knowledge about condition-specific therapies would contribute to income growth.

Increases in aged residents who are more susceptible to rheumatoid arthritis, increasing pervasiveness rates, and the deployment of new helpful experts are among the key expansion development drivers of the Global Rheumatoid Arthritis Drugs Market. The global rheumatoid arthritis drugs industry faces significant limitations and challenges due to factors like the lack of protection inclusion for some medications in developing countries, the patent expiration of some blockbuster drugs, and the inaccessibility of the treatment. As a result, Rheumatoid Arthritis Drugs Market was US$ 34.47 Billion in 2022.

Due to their faster and more efficient operation compared to oral treatments, injectable therapies for rheumatoid arthritis are currently dominating the market
By Product Type, Rheumatoid Arthritis Drugs Market is divided into Oral, Parenteral and Tropical. Injectable pharmaceuticals provide higher bioavailability, enhancing drugs absorption and improving therapeutic effects in rheumatoid arthritis. Given the disease's complexity, advanced biologics are necessary, typically requiring injection administration. Injectable-biologic medications are chosen by doctors to treat rheumatoid arthritis due to their ability to selectively target the underlying immunological systems of the disease and their established efficacy in providing customized care.

Biopharmaceuticals lead the rheumatoid arthritis treatment industry due to their precise targeting of immune pathways

Rheumatoid Arthritis Drugs Market is divided into pharmaceuticals and bio-pharmaceuticals based on therapeutic molecules. By lowering inflammation, preventing joint degeneration, and greatly enhancing pain relief, joint function, and quality of life, these cutting-edge drugs, like TNF inhibitors and interleukin inhibitors, revolutionize treatment. As rheumatoid arthritis processes are more understood, novel, and targeted biopharmaceutical therapies are being developed, solidifying their position as the top therapeutic modules on the market.

Pharmaceutical analgesics are rapidly growing in the rheumatoid arthritis treatment market due to their effectiveness in providing pain relief and compatibility with other medications

By Pharmaceuticals, Rheumatoid Arthritis Treatment Market is comprised of Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Analgesics, Anti-tumour necrosis factor (TNF), and Others. Analgesics provide relief from the debilitating pain experienced by individuals with rheumatoid arthritis, addressing a primary concern. They provide a non-invasive therapy alternative, which appeals to people who choose to stay away from invasive treatments or have medical conditions that would preclude using other options. Patients choose pain treatments for rheumatoid arthritis from various formulations like pills, creams, and patches, often combining them with other medications. Their ability to be combined with other therapies enables a holistic strategy for rheumatoid arthritis pain and inflammation control, which has contributed to their quick market expansion.

Biosimilars have the highest share in the rheumatoid arthritis drugs market

By Bio-Pharmaceuticals, Rheumatoid Arthritis Drugs Market is sub-divied into Bio-pharmaceuticals, Biologics, and Biosimilars. Biosimilars offer comparable efficacy and safety to reference biologics at a lower cost, making them attractive to patients and healthcare providers. Patent expirations have created opportunities for biosimilar manufacturers, driving competition and market share. Regulatory authorities ensure their quality, safety, and efficacy, boosting confidence. Healthcare systems and insurance providers promote biosimilars to reduce costs and improve access to biologics.

The market for treating rheumatoid arthritis is seeing steroid surgery increase quickly due to several variables

By Surgery, Rheumatoid Arthritis Drugs Market is categorized into Nonsteroidal Anti-inflammatory Drugs Type, Steroids, and Biologic Agents. The powerful anti-inflammatory effects of steroids successfully reduce rheumatoid arthritis pain and inflammation. Direct joint injections that provide targeted relief improve symptom management. Due to the minimally invasive nature of steroid surgery, patients can quickly return to their regular activities after an outpatient procedure. Demand for steroid surgery as a non-surgical alternative is fuelled by an increasing desire for conservative methods. Systemic side effects related to oral corticosteroids are minimized by the targeted and transient nature of steroid injections. Steroid surgery is more affordable than biologic medications or surgery, which attracts consumers and healthcare systems and fuels its quick market expansion.

Prescription sales channels will dominate the rheumatoid arthritis drugs market due to the condition's complexity and the need for medical diagnosis and ongoing monitoring

By Sales Channel, Rheumatoid Arthritis Drugs Market is fragmented into Over-the-counter (OTC), and Prescription. Healthcare professionals play a crucial role in prescribing appropriate medications and providing personalized treatment plans. Prescription sales channels offer higher assurance in medication quality, authenticity, and safety, ensuring proper dosage instructions and patient monitoring. The development of innovative therapies, such as biologic drugs, requires specialized knowledge for prescription and administration, which prescription sales channels provide. The rise of telemedicine and digital healthcare platforms further supports the growth of prescription sales channels, offering convenient access to healthcare providers. Regulatory frameworks and healthcare policies also mandate authorized channels for dispensing prescription medications, ensuring compliance and patient safety.

Online distribution channels are set for substantial growth in the future of the rheumatoid arthritis drugs market.

By Distribution Channel, Rheumatoid Arthritis drugs Market is broken up into Hospital Pharmacies, Retail Pharmacies, and Online. Patients can now order drugs from home thanks to the growth of e-commerce and digital platforms, which have increased the accessibility and convenience of healthcare items. As telemedicine is used more frequently, virtual consultations and electronic prescriptions are made possible, making it easier to buy medications online. Patients gain by having access to a variety of products, lower prices, and information and support services. These elements have a role in the market for treating rheumatoid arthritis' considerable expansion of online distribution channels.

In North America, rheumatoid arthritis drugs should continue to hold a substantial market share

Based on Region, Rheumatoid Arthritis drugs Market is divided into North America, South America, Europe, Asia-Pacific, and Rest of World. The rising disease prevalence, the dominance of major market players, the rising introduction of novel therapies like monoclonal antibodies for rheumatoid arthritis, and the rising investments made by major market players in the development of new therapies and biosimilars for this condition are all expected to contribute to the market for the region under study expanding.

The Centers for Disease Control and Prevention (CDC) estimate that approximately 1 in 4 adults in the United States (23.7%), or 58.5 million people, have arthritis as determined by medical professionals. The high prevalence of rheumatoid arthritis and the corresponding demand for pharmaceutical treatments are driving market expansion.

United States will register substantial growth in the rheumatoid arthritis treatment market

The Rheumatoid Arthritis drugs Market is segmented into the following countries: the United States, Canada, Mexico, the United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Indonesia, Brazil, Argentina, Saudi Arabia, the United Arab Emirates, South Africa, and Other Countries. Due to its powerful regulatory environment, big patient population, innovative pharmaceutical industry, and strong healthcare infrastructure, the US leads the world in rheumatoid arthritis treatment. It is possible to receive a prompt diagnosis, have access to specialists, and choose from a variety of treatments. The United States is a centre for pharmaceutical research that produces cutting-edge treatments. Investment in research and development is attracted by the strong market demand and the supportive environment. The US FDA provides assurances of efficacy and safety, fostering trust. The availability and affordability of treatments are improved by insurance coverage.

Competitive Landscape

Among the top competitors present in the rheumatoid arthritis drugs market are Eli Lilly and Co., Fibrogen Inc., Biogen Inc., Merck & Co. Inc., Abbvie Inc., Roche Holding AG, Novartis AG, and Johnson & Johnson.

In February 2022- Biogen Inc. and XbraneBiopharma AB signed a commercialization and license agreement to create, produce, and sell Xcimzane. The rheumatoid arthritis medication CIMZIA (certolizumabpegol) has a suspected biosimilar in this preclinical monoclonal antibody.

Renub Research latest report “Rheumatoid Arthritis Drugs Market, Product Types (Oral, Parenteral, Tropical), Therapeutic Molecules (Pharmaceuticals, and Bio-pharmaceuticals), Pharmaceuticals (Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, Analgesics, Anti-tumour necrosis factor (TNF), and Others), Bio-Pharmaceuticals (Bio-pharmaceuticals, Biologics, and Biosimilars), Surgery (Nonsteroidal Anti-inflammatory Drugs Type, Steroids, and Biologic Agents), Sales Channel (Over-the-counter (OTC), and Prescription), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online), Regions (North America, South America, Europe, Asia-Pacific, and ROW), Countries (United States, Canada, Mexico, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Indonesia, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Other Countries), Companies (Eli Lilly and Co., Fibrogen Inc., Biogen Inc., Merck & Co. Inc, Abbvie Inc., Roche Holding AG, Novartis AG, Johnson & Johnson)” provides a detailed analysis of Rheumatoid Arthritis Drugs Industry.

Product Types – Market has been covered from 3 viewpoints:

1. Oral
2. Parenteral
3. Tropical

Therapeutic Molecules – Market has been covered from 2 viewpoints:

1. Pharmaceuticals
2. Bio-pharmaceuticals

Pharmaceuticals – Market has been covered from 7 viewpoints:

1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
3. Corticosteroids
4. Uric Acid Drugs
5. Analgesics
6. Anti-tumour necrosis factor (TNF)
7. Others

Bio-Pharmaceuticals – Market has been covered from 3 viewpoints:

1. Bio-pharmaceuticals
2. Biologics
3. Biosimilars

Surgery – Market has been covered from 3 viewpoints:

1. Nonsteroidal Anti-inflammatory Drugs Type
2. Steroids
3. Biologic Agents

Sales Channel – Market has been covered from 2 viewpoints:

1. Over-the-counter (OTC)
2. Prescription

Distribution Channel – Market has been covered from 3 viewpoints:

1. Hospital Pharmacies
2. Retail Pharmacies
3. Online

Region – Market has been covered from 5 viewpoints:

1. North America
2. South America
3. Europe
4. Asia-Pacific
5. Rest of World

Countries – Market has been covered from 22 Countries:

1. North America

1.1 United States
1.2 Canada
1.3 Mexico

2. Europe

2.1 United Kingdom
2.2 Germany
2.3 France
2.4 Russia
2.5 Italy
2.6 Spain
2.7 Switzerland

3. Asia-Pacific

3.1 India
3.2 China
3.3 Japan
3.4 Australia
3.5 South Korea
3.6 Indonesia

4. Middle East & Africa

4.1 Saudi Arabia
4.2 United Arab Emirates
4.3 South Africa

5. South America

5.1 Argentina
5.2 Brazil
5.3 Other Countries

6. Rest of World

Company Insights:

• Overview
• Recent Development
• Revenue

Company Analysis:

1. Eli Lilly and Co.
2. Fibrogen Inc.
3. Biogen Inc.
4. Merck & Co. Inc
5. Abbvie Inc.
6. Roche Holding AG
7. Novartis AG
8. Johnson & Johnson


1. Introduction
2. Research& Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Rheumatoid Arthritis Drug Market
6. Rheumatoid Arthritis Drug Market – Share Analysis
6.1 By Product Type
6.2 By Therapeutic Molecules
6.2.1 By Pharmaceuticals
6.2.2 By Bio-pharmaceuticals
6.3 By Surgery
6.4 By Sales Channel
6.5 By Distribution Channel
6.6 By Region
6.7 By Country
7. Product Type – Rheumatoid Arthritis Drug Market
7.1 Oral
7.2 Parenteral
7.3 Tropical
8. Therapeutic Molecules – Rheumatoid Arthritis Drug Market
8.1 Pharmaceuticals
8.1.1 Disease-modifying Anti-rheumatic Drugs (DMARDs)
8.1.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
8.1.3 Corticosteroids
8.1.4 Uric Acid Drugs
8.1.5 Analgesic
8.1.6 Anti-tumor necrosis factor (TNF)
8.1.7 Others
8.2 Biopharmaceuticals
8.2.1 Biologics
8.2.2 Biosimilars
9. Surgery – Rheumatoid Arthritis Drug Market
9.1 Nonsteroidal Anti-inflammatory Drug Type
9.2 Steroids
9.3 Biologic Agents
10. Sales Channel – Rheumatoid Arthritis Drug Market
10.1 Over-The-Counter (OTC)
10.2 Prescription
11. Distribution Channel – Rheumatoid Arthritis Drug Market
11.1 Hospital Pharmacies
11.2 Retail Pharmacies
11.3 Online
12. Country – Rheumatoid Arthritis Drug Market
12.1 North America
12.1.1 United States
12.1.2 Canada
12.1.3 Mexico
12.2 Europe
12.2.1 United Kingdom
12.2.2 Germany
12.2.3 France
12.2.4 Russia
12.2.5 Italy
12.2.6 Spain
12.2.7 Switzerland
12.3 Asia-Pacific
12.3.1 India
12.3.2 China
12.3.3 Japan
12.3.4 Australia
12.3.5 South Korea
12.4 Middle East & Africa
12.4.1 Indonesia
12.4.2 Saudi Arabia
12.4.3 United Arab Emirates
12.4.4 South Africa
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Other Countries
12.6 Rest of World
13. Rheumatoid Arthritis Drug Market - Porter's Five Forces Analysis
13.1 Threat of New Entry
13.2 The Bargaining Power of Buyer
13.3 Threat of Substitution
13.4 The Bargaining Power of Supplier
13.5 Competitive Rivalry
14. Rheumatoid Arthritis Drug Market – SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats
15. Key Players
15.1 Eli Lilly and Co
15.1.1 Overview
15.1.2 Recent Development
15.1.3 SWOT Analysis
15.1.4 Revenue
15.2 Fibrogen Inc.
15.2.1 Overview
15.2.2 Recent Development
15.2.3 SWOT Analysis
15.2.4 Revenue
15.3 BiogenInc
15.3.1 Overview
15.3.2 Recent Development
15.3.3 SWOT Analysis
15.3.4 Revenue
15.4 Merck & co Inc
15.4.1 Overview
15.4.2 Recent Development
15.4.3 SWOT Analysis
15.4.4 Revenue
15.5 Abbvie Inc
15.5.1 Overview
15.5.2 Recent Development
15.5.3 SWOT Analysis
15.5.4 Revenue
15.6 Roche Holding AG
15.6.1 Overview
15.6.2 Recent Development
15.6.3 SWOT Analysis
15.6.4 Revenue
15.7 Novartis AG
15.7.1 Overview
15.7.2 Recent Development
15.7.3 SWOT Analysis
15.7.4 Revenue
15.8 Johnson & Johnson
15.8.1 Overview
15.8.2 Recent Development
15.8.3 SWOT Analysis
15.8.4 Revenue
List of Figures:
Figure-01: Global – Rheumatoid Arthritis Drug Market (Billion US$), 2017 – 2022
Figure-02: Global – Forecast for Rheumatoid Arthritis Drug Market (Billion US$), 2023 – 2030
Figure-03: Product Type – Oral Market (Billion US$), 2017 – 2022
Figure-04: Product Type – Forecast for Oral Market (Billion US$), 2023 – 2030
Figure-05: Product Type – Parenteral Market (Billion US$), 2017 – 2022
Figure-06: Product Type – Forecast for Parenteral Market (Billion US$), 2023 – 2030
Figure-07: Product Type – Tropical Market (Billion US$), 2017 – 2022
Figure-08: Product Type – Forecast for Tropical Market (Billion US$), 2023 – 2030
Figure-09: Therapeutic Molecules – Pharmaceuticals Market (Billion US$), 2017 – 2022
Figure-10: Therapeutic Molecules – Forecast for Pharmaceuticals Market (Billion US$), 2023 – 2030
Figure-11: Therapeutic Molecules – Disease-modifying Anti-rheumatic Drugs (DMARDs) Market (Million US$), 2017 – 2022
Figure-12: Therapeutic Molecules – Forecast for Disease-modifying Anti-rheumatic Drugs (DMARDs) Market (Million US$), 2023 – 2030
Figure-13: Therapeutic Molecules – Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market (Million US$), 2017 – 2022
Figure-14: Therapeutic Molecules – Forecast for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market (Million US$), 2023 – 2030
Figure-15: Therapeutic Molecules – Corticosteroids Market (Million US$), 2017 – 2022
Figure-16: Therapeutic Molecules – Forecast for Corticosteroids Market (Million US$), 2023 – 2030
Figure-17: Therapeutic Molecules – Uric Acid Drugs Market (Million US$), 2017 – 2022
Figure-18: Therapeutic Molecules – Forecast for Uric Acid Drugs Market (Million US$), 2023 – 2030
Figure-19: Therapeutic Molecules – Analgesic Market (Million US$), 2017 – 2022
Figure-20: Therapeutic Molecules – Forecast for Analgesic Market (Million US$), 2023 – 2030
Figure-21: Therapeutic Molecules – Anti-tumor necrosis factor (TNF) Market (Million US$), 2017 – 2022
Figure-22: Therapeutic Molecules – Forecast for Anti-tumor necrosis factor (TNF) Market (Million US$), 2023 – 2030
Figure-23: Therapeutic Molecules – Others Market (Million US$), 2017 – 2022
Figure-24: Therapeutic Molecules – Forecast for Others Market (Million US$), 2023 – 2030
Figure-25: Therapeutic Molecules – Biopharmaceuticals Market (Million US$), 2017 – 2022
Figure-26: Therapeutic Molecules – Forecast for Biopharmaceuticals Market (Million US$), 2023 – 2030
Figure-27: Therapeutic Molecules – Biologics Market (Million US$), 2017 – 2022
Figure-28: Therapeutic Molecules – Forecast for Biologics Market (Million US$), 2023 – 2030
Figure-29: Therapeutic Molecules – Biosimilars Market (Million US$), 2017 – 2022
Figure-30: Therapeutic Molecules – Forecast for Biosimilars Market (Million US$), 2023 – 2030
Figure-31: Surgery – Nonsteroidal Anti-inflammatory Drug Type Market (Billion US$), 2017 – 2022
Figure-32: Surgery – Forecast for Nonsteroidal Anti-inflammatory Drug Type Market (Billion US$), 2023 – 2030
Figure-33: Surgery – Steroids Market (Billion US$), 2017 – 2022
Figure-34: Surgery – Forecast for Steroids Market (Billion US$), 2023 – 2030
Figure-35: Surgery – Biologic Agents Market (Billion US$), 2017 – 2022
Figure-36: Surgery – Forecast for Biologic Agents Market (Billion US$), 2023 – 2030
Figure-37: Sales Channel – Over-The-Counter (OTC) Market (Billion US$), 2017 – 2022
Figure-38: Sales Channel – Forecast for Over-The-Counter (OTC) Market (Billion US$), 2023 – 2030
Figure-39: Sales Channel – Prescription Market (Billion US$), 2017 – 2022
Figure-40: Sales Channel – Forecast for Prescription Market (Billion US$), 2023 – 2030
Figure-41: Distribution Channel – Hospital Pharmacies Market (Billion US$), 2017 – 2022
Figure-42: Distribution Channel – Forecast for Hospital Pharmacies Market (Billion US$), 2023 – 2030
Figure-43: Distribution Channel – Retail Pharmacies Market (Billion US$), 2017 – 2022
Figure-44: Distribution Channel – Forecast for Retail Pharmacies Market (Billion US$), 2023 – 2030
Figure-45: Distribution Channel – Online Market (Billion US$), 2017 – 2022
Figure-46: Distribution Channel – Forecast for Online Market (Billion US$), 2023 – 2030
Figure-47: United States – Rheumatoid Arthritis Drug Market (Billion US$), 2017 – 2022
Figure-48: United States – Forecast for Rheumatoid Arthritis Drug Market (Billion US$), 2023 – 2030
Figure-49: Canada – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-50: Canada – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-51: Mexico – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-52: Mexico – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-53: United Kingdom – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-54: United Kingdom – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-55: Germany – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-56: Germany – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-57: France – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-58: France – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-59: Russia – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-60: Russia – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-61: Italy – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-62: Italy – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-63: Spain – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-64: Spain – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-65: Switzerland – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-66: Switzerland – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-67: India – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-68: India – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-69: China – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-70: China – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-71: Japan – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-72: Japan – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-73: Australia – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-74: Australia – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-75: South Korea – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-76: South Korea – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-77: Indonesia – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-78: Indonesia – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-79: Saudi Arabia – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-80: Saudi Arabia – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-81: United Arab Emirates – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-82: United Arab Emirates – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-83: South Africa – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-84: South Africa – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-85: Argentina – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-86: Argentina – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-87: Brazil – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-88: Brazil – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-89: Other Countries – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-90: Other Countries – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-91: Rest of World – Rheumatoid Arthritis Drug Market (Million US$), 2017 – 2022
Figure-92: Rest of World – Forecast for Rheumatoid Arthritis Drug Market (Million US$), 2023 – 2030
Figure-93: Eli Lilly and Co – Global Revenue Market (Billion US$), 2017 – 2022
Figure-94: Eli Lilly and Co – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-95: Fibrogen Inc. – Global Revenue Market (Billion US$), 2017 – 2022
Figure-96: Fibrogen Inc. – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-97: BiogenInc – Global Revenue Market (Billion US$), 2017 – 2022
Figure-98: BiogenInc – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-99: Merck & co Inc – Global Revenue Market (Billion US$), 2017 – 2022
Figure-100: Merck & co Inc – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-101: AbbvieInc – Global Revenue Market (Billion US$), 2017 – 2022
Figure-102: AbbvieInc – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-103: Roche Holding AG – Global Revenue Market (Billion US$), 2017 – 2022
Figure-104: Roche Holding AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-105: Novartis AG – Global Revenue Market (Billion US$), 2017 – 2022
Figure-106: Novartis AG – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
Figure-107: Johnson & Johnson – Global Revenue Market (Billion US$), 2017 – 2022
Figure-108: Johnson & Johnson – Forecast for Global Revenue Market (Billion US$), 2023 – 2030
List of Tables:
Table-01: Global – Rheumatoid Arthritis Drug Market Share by Product Type (Percent), 2017 – 2022
Table-02: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Product Type (Percent), 2023 – 2030
Table-03: Global – Rheumatoid Arthritis Drug Market Share by Therapeutic Molecules (Percent), 2017 – 2022
Table-04: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Therapeutic Molecules (Percent), 2023 – 2030
Table-05: Global – Rheumatoid Arthritis Drug Market Share by Pharmaceuticals (Percent), 2017 – 2022
Table-06: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Pharmaceuticals (Percent), 2023 – 2030
Table-07: Global – Rheumatoid Arthritis Drug Market Share by Bio-pharmaceuticals (Percent), 2017 – 2022
Table-08: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Bio-pharmaceuticals (Percent), 2023 – 2030
Table-09: Global – Rheumatoid Arthritis Drug Market Share by Surgery (Percent), 2017 – 2022
Table-10: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Surgery (Percent), 2023 – 2030
Table-11: Global – Rheumatoid Arthritis Drug Market Share by Sales Channel (Percent), 2017 – 2022
Table-12: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Sales Channel (Percent), 2023 – 2030
Table-13: Global – Rheumatoid Arthritis Drug Market Share by Distribution Channel (Percent), 2017 – 2022
Table-14: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Distribution Channel (Percent), 2023 – 2030
Table-15: Global – Rheumatoid Arthritis Drug Market Share by Country (Percent), 2017 – 2022
Table-16: Global – Forecast for Rheumatoid Arthritis Drug Market Share by Country (Percent), 2023 – 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings